3 news items
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
LRMR
20 May 24
further characterization of frataxin PD at the 25 mg dose. The OLE study is evaluating the long-term safety as well as frataxin levels following daily
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
LRMR
9 May 24
sites. We are on track to report interim data in the fourth quarter of the year which will inform on the long-term safety and tissue frataxin levels
Larimar Therapeutics Announces The Dosing Of The First Patient In Long-Term Open Label Extension Study For Nomlabofusp In Patients With Friedreich's Ataxia
LRMR
11 Mar 24
Study will inform on long-term safety profile and tissue frataxin levels
OLE initiated with 25 mg daily subcutaneous
- Prev
- 1
- Next